Table 1 Results from the all outcomes trials with the major fibrates (gemfibrozil, bezafibrate, fenofibrate)
Study | Primary analysis: RRR (p value) | Subgroup criteria | Subgroup analysis: |
|---|---|---|---|
(Treatment) | RRR (p value) | ||
−34% (<0.02) | TG >200 mg/dL | −71% (0.005) | |
(Gemfibrozil) | LDL-C/HDL-C >5.0 | ||
VA-HIT[44] | −22% (0.006) | Diabetes | −34% (0.004) |
(Gemfibrozil) | |||
BIP[42] | −9.4% (0.24) | TG >200 mg/dL, | −42% (0.02) |
(Bezafibrate) | HDL-C < 35 mg/dL, | ||
−11% (0.16) | TG ≥200 mg/dL | −27% (0.005) | |
(Fenofibrate) | HDL-C <40 mg/dL for men, <50 mg/dL for women | ||
ACCORD Lipid[39] | −8% (0.32) | TG ≥204 mg/dL | −31% (0.03) |
(Fenofibrate) | HDL-C ≤34 mg/dL |